r/SNDL • • 4h ago

Discussion SNDL: The Earnings Potential Hidden Within Its U.S. Investments

8 Upvotes

this is worth a read, so I copied and pasted since Reddit would not allow the link to the article

Summary
SNDL Inc. trades at a substantial discount to book and tangible book value, despite significant underlying asset value and U.S. cannabis exposure.
SNDL's investments in Parallel and Skymint, via SunStream Bancorp, offer material unrecognized earnings potential, with combined 2025 revenue of CAD 265 million.
Recent restructuring and increased ownership in Parallel position SNDL to benefit from U.S. cannabis market integration and regulatory tailwinds.
I rate SNDL a Speculative Buy due to undervaluation, improving operations, and asymmetric upside versus already-reflected downside risk.
Editor's note: Seeking Alpha is proud to welcome Daniel Klim as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.

Investment Thesis
SNDL Inc. (SNDL) presents an interesting investment opportunity because of the gap between its current valuation and the potential earnings of its underlying assets. The company operates a considerable Canadian liquor and cannabis business, but what I find particularly interesting is its investment portfolio.
Through SunStream Bancorp, SNDL maintains investments in several U.S. cannabis businesses whose revenue is not directly consolidated into its financial statements. Two of these investments, Parallel and Skymint, generated approximately CAD 265 million in combined revenue during 2025, according to SNDL's investor presentation. With the recent restructuring of Parallel and SNDL's increased indirect equity interest to approximately 92%, I believe the company is in a better position to benefit from these investments going forward.
What interests me is the possibility that the company's current financial statements are not giving investors a complete picture of its future earnings potential. This is especially important given the substantial discount to book value at which the company currently trades.
SNDL's Existing Operations
SNDL operates through four segments: liquor retail, cannabis retail, cannabis operations and investments. For this analysis, I will use the most recent quarterly results alongside the trailing twelve months ending September 30, 2026. This is important because SNDL experiences considerable seasonality, with Q1 generally being the weakest quarter and Q4 the strongest.
Liquor Retail
According to SNDL's Q3 2026 results, the company operates 165 liquor retail locations through brands including Ace Liquor, Liquor Depot, and Wine and Beyond. During the quarter, the segment generated CAD 134.8 million in revenue and CAD 6.0 million in operating income, while trailing twelve-month revenue reached approximately CAD 522.4 million.
Although same-store sales declined 6.0% during the quarter, gross margins improved to a record 27.0%. I view liquor retail as a relatively stable and profitable part of the business. It isn't where I expect most of the future growth to come from, but it does provide an established source of earnings.
Cannabis Retail
SNDL operates 193 cannabis retail locations, including franchises, mainly through Value Buds and Spiritleaf. During Q3 2026, the segment generated CAD 85.6 million in revenue and CAD 5.2 million in operating income. Over the trailing twelve months, revenue reached approximately CAD 329.4 million, based on the company's latest financial results.
Despite a 3.8% decline in same-store sales, the segment continued to perform relatively well, supported by new locations and improving margins. I also think the company's experience operating such a large cannabis retail network could become useful when considering the potential integration of its U.S. investments.
Cannabis Operations
Cannabis operations remain the company's weakest business. During Q3 2026, revenue declined 27.7% year over year to CAD 27.0 million, while trailing twelve-month revenue reached approximately CAD 125.8 million. The segment recorded an operating loss of CAD 64.7 million during the quarter, including approximately CAD 52 million in goodwill impairment. Even excluding impairment and restructuring costs, the segment recorded an adjusted operating loss of CAD 11.4 million.
In my opinion, much of this quarter's reported loss was one-off. The majority came from the goodwill impairment, while additional losses were tied to inventory adjustments and the company's decision to exit the unprofitable dried flower category. This has naturally led to a decline in revenue and additional pressure on operating profitability as the company changes its focus. Going forward, I expect these changes to improve the segment's profitability, although the adjusted operating loss demonstrates that there are still underlying issues to address.
Consolidated Performance
Over the trailing twelve months ending September 30, 2026, SNDL generated approximately CAD 922.2 million in consolidated revenue, compared with CAD 946.4 million during the full calendar year 2025, using its 2025 annual results and the latest nine-month figures.
During Q3 2026, the company recorded an operating loss of CAD 48.3 million, largely because of the impairment mentioned earlier. However, adjusted operating income reached CAD 5.2 million, compared with an adjusted operating loss of CAD 9.5 million during Q3 2025.
While I find this improvement encouraging, it should be noted that CAD 7.9 million of operating income came from the investment segment, including CAD 6.9 million in equity-accounted profits mainly related to an increase in Parallel's valuation. This means the company's Canadian operations still have considerable room for improvement, which is something I expect management's recent changes to address.
The Investment Portfolio
SNDL holds a 50% ownership interest in SunStream Bancorp, a joint venture through which it has invested in several U.S. cannabis businesses. Because SunStream is accounted for using the equity method, SNDL recognizes its share of the investment's results rather than directly including the underlying businesses' revenue and expenses.
As of September 30, 2026, SNDL's cannabis-related investment portfolio had a carrying value of approximately CAD 485.2 million, of which CAD 467.7 million related to SunStream.
This is where I think the company becomes particularly interesting. Although these investments are already represented on the balance sheet, their underlying operating businesses are not directly reflected in consolidated revenue. As a result, the earning potential of these assets is not immediately apparent when looking at SNDL's income statement.
The two investments I want to focus on are Parallel and Skymint.
Parallel
Parallel originally received a USD 150 million secured loan through SunStream in May 2021. Following financial difficulties, the company underwent a restructuring that was completed on July 27, 2026,eliminating approximately USD 842 million of legacy debt obligations.
During Q3 2026, SNDL participated in a rights offering that increased its indirect equity interest in Parallel from approximately 67% to 92%, as detailed in the company's third-quarter results. To me, this is one of the more important developments in SNDL's investment portfolio, as the company now has substantial economic exposure to an established U.S. cannabis operator.
Parallel operates 56 retail and pickup locations across Florida, Texas, and Massachusetts, alongside three cultivation and manufacturing facilities. According to SNDL's investor presentations, the business generated approximately CAD 212 million in revenue during 2025, down from CAD 257 million in 2024. While the decline is concerning, Parallel continues to maintain approximately USD 150 million in annualized revenue, equivalent to roughly CAD 213 million.
For comparison, that represents approximately 23% of SNDL's current trailing twelve-month revenue.
SNDL is working toward a structure that would allow it to directly consolidate qualifying U.S. medical cannabis operations while maintaining regulatory and Nasdaq compliance. This would mainly concern Parallel's medical operations in Florida and Texas, while adult-use operations, including those in Massachusetts, would remain outside the proposed initial consolidation.
Although this could result in a notable increase in reported revenue, what interests me more is the potential earnings contribution. The company would also have greater influence over how the eligible operations are managed and how capital is allocated.
Unfortunately, Parallel's current profitability is not sufficiently disclosed. However, we can use its existing revenue to understand what different operating margins could mean.
At USD 150 million in annual revenue, a 5% operating margin would produce USD 7.5 million in operating income. At 10%, this would increase to USD 15 million, while a 15% margin would produce USD 22.5 million.
These figures are before taxes, financing costs, and ownership adjustments, so they should not be treated as profits attributable directly to SNDL. However, given SNDL's intention to bring these assets under its direct management, I think it's important to understand the full scope of what could eventually become part of the company's operations. This would represent a significant opportunity for SNDL to expand directly into the U.S. cannabis market, with Parallel potentially serving as its entry point.
Skymint
Skymint is another investment that I believe deserves consideration, although I am considerably less confident in its near-term potential.
The business operates in Michigan through brands including Skymint Premium Cannabis, North Cannabis, and PotCo. Like Parallel, Skymint encountered financial difficulties following financing provided through SunStream and eventually entered receivership proceedings in 2023.
During 2024, Skymint generated approximately CAD 88 million in revenue, which declined to CAD 53 million in 2025. The company also reduced its retail footprint from 19 locations to 17 while moving away from cultivation and manufacturing.
Although the decline in revenue is substantial, I think the change in business structure is worth considering. By focusing primarily on retail, Skymint may be able to reduce some of the fixed costs associated with cultivation. Whether this has actually improved profitability remains unclear.
Using its 2025 revenue of CAD 53 million, a hypothetical operating margin of 5% would produce approximately CAD 2.7 million in operating income. At 10%, this would increase to CAD 5.3 million, while a 15% margin would produce approximately CAD 8.0 million.
Skymint's investment carrying value within SunStream declined from CAD 83.1 million at the end of 2025 to CAD 68.1 million at September 30, 2026. Its restructuring also remains subject to legal proceedings, and its exposure to Michigan's adult-use market creates additional complications.
For these reasons, I view Skymint more as an additional opportunity than something I would base the investment thesis around. However, I still think it represents the possibility of further U.S. expansion through SunStream. Should the restructuring prove successful, Skymint could provide further evidence that SNDL's investment strategy is capable of producing meaningful opportunities beyond its existing Canadian operations.
Combining the Opportunities
Looking at Parallel and Skymint together gives a better idea of the potential importance of SNDL's investment portfolio.
During 2025, the two businesses generated approximately CAD 265 million in combined revenue. For comparison, SNDL generated CAD 946.4 million over the same period. Including both businesses hypothetically would bring combined revenue to approximately CAD 1.21 billion.
Of course, this is not necessarily the amount SNDL will be able to consolidate. The current ownership structure and regulatory restrictions mean some operations may remain outside the company's financial statements. However, I think the comparison helps demonstrate the scale of the investments.
What I find more important is their potential earnings. Using the combined CAD 265 million in revenue, an operating margin of 5% would produce approximately CAD 13.3 million in operating income. At 10%, this would increase to CAD 26.5 million, while a 15% margin would produce CAD 39.8 million.
These figures represent the potential operating income of the underlying businesses, not necessarily the amount SNDL shareholders would receive. Still, the numbers become quite interesting when compared with the company's current financial performance.
In my previous analysis, I considered the possibility of SNDL eventually generating between CAD 1.3 billion and CAD 1.5 billion in annual revenue, with net profit margins of approximately 5% to 7%. This would produce somewhere between CAD 65 million and CAD 105 million in annual net earnings.
Uncertainty remains. Achieving these figures would require improvement in the Canadian businesses, profitable U.S. operations, and additional growth. However, I continue to believe it is a reasonable scenario to examine when considering the company's longer-term potential, especially with the company's current efforts to improve profitability, even at the cost of revenue.
With SNDL's market capitalization at approximately CAD 482 million, CAD 65 million in net earnings would represent a hypothetical P/E ratio of approximately 7.4. At CAD 105 million, the ratio would fall to approximately 4.6.
While these are hypothetical earnings rather than what the company currently generates, I think they demonstrate the potential earnings power of SNDL should it continue improving its operations. This also leads me to believe that some of the company's recent financial difficulties may be more a result of its ongoing restructuring than evidence that the business cannot become profitable. Whether that proves to be the case will depend on how much profitability improves over the coming quarters.
U.S. Regulatory Developments
Another factor worth considering is the changing regulatory environment in the United States.
On April 23, 2026, the U.S. Department of Justice announced a final order moving qualifying medical cannabis activities into Schedule III of the Controlled Substances Act, as explained in the U.S. Treasury and IRS announcement.
This is particularly important because Section 280E restricts ordinary business expense deductions for businesses dealing in Schedule I or II controlled substances. Qualifying medical cannabis operations could therefore benefit from more favourable tax treatment, depending on the applicable rules and further guidance.
I believe this could be particularly beneficial to Parallel because SNDL's proposed integration focuses on medical cannabis operations.
Unlike consolidation, which mainly changes how the business is reported, lower taxes could directly improve earnings and cash generation. However, the benefits should not be assumed to apply to all of Parallel's operations, particularly those involved in adult-use cannabis.
Valuation
SNDL's financial position is another reason I find the company interesting. According to its Q3 2026 financial statements, SNDL reported CAD 132.5 million in unrestricted cash and CAD 485.2 million in cannabis-related investments, giving it approximately CAD 617.7 million in combined cash and investments. Total shareholders' equity stood at approximately CAD 1.01 billion.
Using its November 4 closing price of CAD 1.98 and approximately 243.3 million shares outstanding, SNDL had a market capitalization of roughly CAD 482 million. This represents a price-to-book ratio of approximately 0.48. Even after removing goodwill and intangible assets, tangible book value remained approximately CAD 875.5 million, giving the company a price-to-tangible-book ratio of 0.55.
I find this discount substantial, particularly when compared with other cannabis companies. Using their latest available financial statements and November 4 share prices, Cronos Group (CRON) traded at approximately 1.29 times tangible book value, while Village Farms International(VFF) traded at approximately 1.44 times. These calculations use closing prices of USD 3.51 for Cronos and USD 2.93 for Village Farms. Both companies therefore trade at considerably higher valuations relative to their tangible assets.
However, I don't believe this difference can be attributed entirely to market mispricing. Cronos maintains a particularly strong balance sheet, while Village Farms has demonstrated stronger recent profitability. SNDL, meanwhile, continues to face losses within its cannabis operations and considerable uncertainty surrounding SunStream. For another comparison, High Tide reported CAD 8.7 million in operating income during its third fiscal quarter of 2026, demonstrating the importance of profitability when comparing cannabis businesses.
One of my main concerns when valuing SNDL is the uncertainty surrounding SunStream's carrying value of CAD 467.7 million. To account for this, consider a hypothetical 50% reduction in its value. This would reduce SNDL's tangible book value to approximately CAD 641.7 million, leaving the company trading at roughly 0.75 times adjusted tangible book value. Even under this assumption, SNDL would continue trading at a discount to its reported net tangible assets, although this does not guarantee those assets could be realized at their carrying values.
I also believe the company's potential earnings deserve consideration. As discussed earlier, I see a scenario in which SNDL could eventually generate CAD 65 million to CAD 105 million in annual net earnings. At the November 4 market capitalization, this would represent hypothetical P/E ratios between approximately 7.4 and 4.6. These figures depend on substantial improvements in profitability, but they illustrate why I find the company's longer-term earnings potential interesting.
In my opinion, the current discount reflects genuine concerns surrounding SNDL's profitability and investment portfolio. However, when comparing its valuation with peers and considering potential improvements in Canadian operations alongside the integration of Parallel, I believe the market may be assigning too little value to its opportunities for growth. Should management successfully improve profitability and realize value from SunStream, the current discount could become increasingly difficult to justify.
Capital Allocation and Risks
SNDL's capital allocation is another aspect worth examining.
During Q3 2026, the company reported approximately CAD 20 million in free cash flow under its non-IFRS definition. However, CAD 10.6 million came from the unwinding of a captive insurance arrangement, meaning a substantial portion was nonrecurring.
Despite this positive free cash flow, the company's cash balance declined by approximately CAD 50.7 million. This was largely the result of CAD 60.8 million in strategic U.S. investments and CAD 10 million in share repurchases.
I don't necessarily consider the decline in cash a problem since much of it was used to increase the company's exposure to Parallel. However, the money being invested needs to eventually produce a return.
SNDL has also been actively reducing its outstanding share count. Through October 22, the company had repurchased approximately 23.1 million shares during 2026. Management has also proposed a substantial issuer bid of up to CAD 50 million, subject to approvals.
Given the current discount to book value, I believe the repurchases could be beneficial to shareholders. Nevertheless, I would prefer that the company maintain enough cash to support its existing businesses and take advantage of future opportunities.
As for the risks, the biggest concern is that the investments fail to generate the profits I expect. Parallel has already experienced considerable difficulties and has required substantial additional capital, while Skymint remains subject to litigation and uncertainty surrounding its restructuring.
There is also no guarantee that SNDL will be able to consolidate the eligible U.S. operations, and its Canadian cannabis operations continue to lose money.
If Parallel fails to improve profitability, SunStream requires further substantial write-downs, or the Canadian operations continue consuming cash without improvement, I would have to reconsider the thesis.
Conclusion
SNDL presents an interesting investment opportunity because of the difference between its current market valuation and the potential earnings of its underlying assets.
Through SunStream, the company maintains substantial economic exposure to U.S. cannabis businesses whose operating revenue is not currently represented in its consolidated financial statements. Parallel and Skymint together generated CAD 265 million in revenue during 2025, while their restructuring and potential future integration provide opportunities for stronger financial performance.
At approximately 0.48 times reported book value and 0.55 times tangible book value, SNDL trades at a considerable discount to its reported assets. Some of that discount is understandable given the uncertainty surrounding its investments and the weaknesses of its existing operations. However, given the company's current direction, I would argue that these weaknesses might also represent some of its largest opportunities for improving profitability.
I believe the current valuation does not properly reflect the company's financial position. SNDL has demonstrated an ability to generate cash while maintaining ample opportunities for growth through its investment portfolio, even if the nature of that portfolio makes its potential more difficult to recognize. These two factors together make me believe there is considerable room for the company's earnings and share price to improve.
Furthermore, given the substantial discount to its reported assets, I believe much of the downside risk is already reflected in the current share price. Although the stock could certainly decline further, especially if its investments fail to perform as expected, I believe the potential upside considerably outweighs that risk, leaving room for a significant upswing. For these reasons, I would give SNDL a Speculative Buy rating.

This article was written by
Daniel Klim


r/SNDL • • 4d ago

News SNDL: 3 Key Takeaways for Long-Term Investors

Thumbnail theglobeandmail.com
16 Upvotes

r/SNDL • • 5d ago

News 16 Governors From Across The U.S. Push Congress To Pass Marijuana Banking Bill

Thumbnail
marijuanamoment.net
28 Upvotes

r/SNDL • • 6d ago

News Ottawa Outlines Cannabis Excise Stamp Reforms in 2026 Budget

11 Upvotes

Nov 5th

The federal government’s 2026 Budget proposes streamlining the federal excise stamping program by reducing the number of unique cannabis excise duty stamps from 13 to six.

Budget 2026 outlines revisions to the current cannabis excise duty stamp framework. Under these proposed measures, a unified stamp would cover regions with identical tax rates, such as Québec, Nova Scotia, New Brunswick, British Columbia, Prince Edward Island, Newfoundland and Labrador, Yukon, and the Northwest Territories, while giving other interested jurisdictions an opportunity to opt in. 

Participating provinces and territories must notify the Minister of Finance and National Revenue of their intention to join by January 31, 2027.  Alberta, Saskatchewan, Ontario, and Nunavut, which also have Coordinated Cannabis Taxation Agreements with the federal government, would be invited to adopt the common stamp, and may indicate their desire to do so by the January 31, 2027 deadline.

Under the proposed timeline, licensed producers could start applying the unified stamp on January 1, 2028. Throughout a transitional period ending June 30, 2029, products headed for participating markets may carry either the unified stamp or the existing region-specific stamp when entering the commercial supply chain.

After June 30, 2029, producers must use the unified stamp in those jurisdictions. However, inventory already in commercial channels bearing the legacy stamps may still be sold through wholesale and retail networks until December 31, 2029.

However, this would still not address some industry calls for cross-provincial sales. After entering a province or territory’s commercial supply chain, moving or shipping duty-paid products across borders, even those bearing a unified stamp, would remain largely restricted for commercial purposes.

Producers could, however, receive returned inventory carrying the common stamp and redistribute it into another participating jurisdiction. To do so, producers would have to declare the return and secondary sale while reconciling any tax variance through duty payments or applicable refunds.

Background

This proposed policy change reflects part of what the industry has been asking for for several years. Some in the industry have expected a proposed single, unified federal excise stamp to be included in Budgets 2024 and 2025, but the issue was repeatedly sidelined. 

The federal government imposes an excise duty on cannabis products of $1 per gram on cannabis products sold into the provincial and territorial retail systems, with 75% of that revenue shared with the province or territory. All provinces and territories signed this agreement, except for Manitoba, which collects and remits its own excise. 

Ontario, Saskatchewan, Alberta, and Nunavut have agreements that adjust their share of excise duty based on differences in sales tax. Currently, licensed producers must buy and apply specific regional stamps and pay the exact tax rate for each destination before releasing products into retail channels.

Cannabis producers in Canada selling into these provinces and territories must buy and apply different stamps depending on where the products will be sold. Producers argue this costly, labour-intensive process could be streamlined. 

Updated fines and penalties

The new federal budget also introduces two proposed penalties. The first is a civil fine set at twice the payable duty on any cannabis a licensed producer reports having in stock but cannot account for. 

The second changes how fines and penalties are calculated for specific cannabis products. For violations involving the sale or distribution of unstamped edibles, topicals, and extracts, fines would equal two to three times the duty payable if the product had a THC concentration of: 10 milligrams per gram for cannabis edibles; 15 milligrams per gram for cannabis topicals; and 1000 milligrams per gram for cannabis extracts. This could enable stronger enforcement against those selling unlicensed products.

----

https://stratcann.com/news/ottawa-outlines-cannabis-excise-stamp-reforms-in-2026-budget/#:~:text=Under%20the%20proposed%20timeline%2C%20licensed%20producers%20could,use%20the%20unified%20stamp%20in%20those%20jurisdictions.


r/SNDL • • 6d ago

News No official PR, however a news outlet picked up the EU GMP approval

21 Upvotes

SNDL receives EU-GMP Certification for Atholville Facility

https://stratcann.com/news/sndl-receives-eu-gmp-certification-for-atholville-facility/

----

SNDL Inc. has received European Union Good Manufacturing Practice (EU GMP) certification for its Atholville, New Brunswick facility.

Granted on Nov. 4, 2026, the certification covers the production and packaging of cannabis flower designated for regulated medical cannabis markets. 

“With lighting upgrades now underway, we continue to invest in Atholville’s capabilities and position the facility to participate in regulated international medical cannabis markets,” said SNDL CEO Zachary George.

“We recognize and thank the Atholville team, along with employees across SNDL, whose dedication and expertise made this important milestone possible.”

The Alberta-based company announced on August 4, 2026, that it received the certification inspection, which SNDL said reinforces its ability to participate in regulated international medical cannabis markets and reflects its continued focus on operational excellence and regulatory compliance. 

EU-GMP compliance is an important standard for supplying medical cannabis products into many international jurisdictions. SNDL’s international sales also increased from $3.8 million in the second quarter of 2025 to $5 million in the second quarter of 2026.

SNDL is headquartered in Edmonton, Alberta, with operations in Kelowna, British Columbia; Bolton and London, Ontario; Toronto, Ontario; and Atholville, New Brunswick, and corporate-owned, controlled, and franchised retail liquor and cannabis stores in five provinces across Canada. 

Atholville is one of SNDL’s largest cultivation assets, comprising approximately 380,000 square feet with more than 110,000 square feet of cultivation canopy and production capacity supporting approximately 4,500 kilograms per quarter, with the potential to support greater than 30 tonnes with targeted investment. Zenabis previously owned the facility. 

SNDL Inc., through its wholly owned subsidiaries, is one of Canada’s largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer, with retail banners including Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Cost Cannabis. 

SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future, and Bhang Chocolate. 

SNDL Inc. reported net revenue of $238 million in the three months ended September 30 (Q3 2026), gross profit of $57.9 million, and a net loss of $50.8 million.


r/SNDL • • 10d ago

News SNDL has now officially received European Union Good Manufacturing Practice (EU GMP) certification for its Atholville, New Brunswick facility.

Post image
48 Upvotes

r/SNDL • • 13d ago

News DEA Officially Grants Federal Registration And Protections To More Than 900 Medical Marijuana Dispensaries

23 Upvotes

Benefits Sunstream's TX and FL assets -------> Since the DEA explicitly excluded operators located in "dual-use" states, federal protections, specifically IRS Section 280E tax relief and closed-loop federal banking, are now geographically quarantined.

https://www.marijuanamoment.net/dea-officially-grants-federal-registration-and-protections-to-more-than-900-medical-marijuana-dispensaries/

----

The Trump administration has issued federal registrations to hundreds of medical marijuana dispensaries in states across the U.S. in line with the process of federally rescheduling cannabis, Attorney General Todd Blanche has announced.

“The American people deserve access to the best medical treatments in the world,” the attorney general said on Friday. “The regulated distribution of medical marijuana by the applicants that have been granted registration by the Drug Enforcement Administration will help ensure broader access to chronic pain treatment and the safety of the American people.”

“The Department of Justice will continue prosecuting illegal marijuana trafficking and related criminal activity in accordance with federal law,” he added.

The Department of Justice said the registrations “mark the first phase of implementing” marijuana rescheduling.

The initial registrations include more than 900 dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

The first batch of registrations is being granted to businesses that submitted their applications during a 60-period for expedited consideration.

DEA separately announced on Friday that nearly 7,000 medical marijuana businesses have already applied for federal protections under rescheduling.

The agency began accepting registrations from medical cannabis dispensaries with a new form in April, days after Attorney General Todd Blanche issued an order immediately moving marijuana products regulated by a state medical cannabis license from Schedule I of the Controlled Substances Act (CSA) to Schedule III, along with marijuana products that are approved by the Food and Drug Administration (FDA).

Earlier this month, DEA launched new specialized registration forms for additional types of state-licensed medical marijuana businesses such as manufacturers, distributors and analytical labs.

A DEA hearing that recently concluded testimony is considering broader marijuana rescheduling beyond medical cannabis.

“State licensure alone does not automatically grant federal registration,” DOJ said on Friday. “Registered dispensaries will be subject to applicable federal requirements, including security, recordkeeping, inventory controls, and other safeguards governing the handling of controlled substances.”

DEA will continue processing dispensary applications and issuing registrations “through a phased registration process,” the department said, while also beginning to consider registration applications from medical cannabis manufacturers and distributors, which require additional review such as facility inspections, production controls and quota determinations.


r/SNDL • • 18d ago

News Post-Q3 Earnings: Is SNDL Stock a Portfolio Must-Have?

Thumbnail theglobeandmail.com
19 Upvotes

r/SNDL • • 18d ago

News The owner of Ace Liquor and Spiritleaf raises its bet on U.S. cannabis, as its manufacturing arm faces a strategic review

Thumbnail
ca.news.yahoo.com
21 Upvotes

r/SNDL • • 20d ago

News SNDL Q3 EARNINGS REPORT NEWS UPDATE:

Thumbnail
sndl.com
17 Upvotes

r/SNDL • • 20d ago

Discussion How will SNDL Leverage Sunstream to Create International Credit Facilities?

9 Upvotes

With the potential for an OGI-ACB partnership or merger, both are Internationally aligned and focused, specifically in Germany and UK, just curious how SNDL will leverage Sunstream Internationally?

----

HITI's Remexian could be leveraged to acquire International assets - 14% of the German market, 900k patients. HITI has a Put/Call option for the remaining 49% of Remexian which becomes available Sept 2027.

SNDL still owns 4% of HITI.

----

Would Sunstream or an international proxy (Remexian) buy assets in Czech, which borders Germany, and is less expensive to operate. Or perhaps, the UK? Or, Poland? They are following the German model.

Canadian firms have CETA advantages selling into the EU - no tariffs, 'frictionless' entry for medical products - EU GMP (Atholville) + CDL and DEL licenses (HYTN partnership).

The next wave is International, specifically with highest margin cannabis 2.0 products.


r/SNDL • • 21d ago

Discussion SNDL OCT. 27 EARNINGS Let's dive into our biggest catalysts

22 Upvotes

🌿 SNDL Q3 Earnings Watch — October 27 📈

Consensus EPS is around -$0.02, but here's what I'm watching for potential upside surprises:

🔹 EPS & EBITDA: Can SNDL narrow its losses and show stronger underlying profitability?

🔹 💰 Free cash flow: SNDL preliminarily reported a record ~$20M in Q3 free cash flow. How much is sustainable?

🔹 🇪🇺 EU-GMP certification: Any update on Atholville certification and readiness to export into European medical cannabis markets.

🔹 📦 European sales orders: Confirmation of purchase orders, export contracts, or initial shipments could be a major growth catalyst.

🔹 🔥 Jeeter: Evidence the Canadian launch is translating into sales and margins.

🔹 🇺🇸 SunStream & Parallel: Asset recoveries, improved valuations, and progress integrating Parallel.

🔹 💵 $50M share buyback bid: Updates on timing and execution could support the shareholder-return story.

My biggest question: Can SNDL combine improving financials with new growth catalysts? A small EPS beat is nice, but sustainable profitability, European orders, and capital returns could matter much more.

👀 Earnings before market open tomorrow. Let's see what management delivers!


r/SNDL • • 23d ago

News Key takeaways from the release "SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives"

26 Upvotes

1. 2026 Shareholder Meeting Results

  • Board & Auditor Approved: Shareholders elected all 5 director nominees and re-appointed the Company's auditor with strong majority support.

  • Share Consolidation Rejected: The special resolution for a potential reverse share split received 54.1% approval, failing to reach the required two-thirds supermajority. Consequently, SNDL will not proceed with the share consolidation.

2. Record Preliminary Q3 2026 Results

  • Highest Free Cash Flow (FCF) in History: SNDL generated approximately C$20 million in FCF for Q3 2026.

  • One-Time Impact: The FCF benefited from a C$10.6 million net gain from unwinding its captive insurance arrangement, alongside operational cash generation and working capital initiatives.

3. Accelerated Capital Return Initiatives

  • Past Repurchases: Over the 12 months ending September 30, 2026, SNDL repurchased ~21.8 million common shares for C$43.4 million (including 5.4 million shares in Q3 alone).

  • Possible Substantial Issuer Bid (SIB): The Board directed management to pursue a potential SIB to buy back up to C$50 million worth of shares at a maximum price of C1.35) per share. This represents a 17.4% premium over the October 14, 2026 closing price.

  • NCIB Renewal: SNDL plans to renew its normal course share repurchase program after its current program expires on November 20, 2026.

4. Strategic & Operational Updates

  • U.S. Medical Cannabis (Parallel / Surterra): SNDL increased its indirect stake in Parallel from 67% to ~92% via a rights offering. Additionally, SunStream is funding a new cultivation/processing facility in Gainesville, Florida, to supply Parallel's retail network.

  • Canadian Cannabis Refocus: SNDL is exiting the unprofitable domestic dried flower market to focus on higher-value products.

  • Ontario Settlement (AGCO): Reached an agreement in principle to settle regulatory matters with the AGCO for a $200K fine, transitioning associated retail locations to a franchise model (which will deconsolidate retail revenue while keeping net economics).


r/SNDL • • 23d ago

News SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives

Thumbnail sndl.com
14 Upvotes

r/SNDL • • 23d ago

News SNDL Agrees to Pay $200,000 Fine and Restructure Franchise Operations under AGCO Deal

Thumbnail
stratcann.com
20 Upvotes

r/SNDL • • 24d ago

News DEA Judge Denies Marijuana Rescheduling Opponents' Request To Reopen Hearing For More Testimony, But Allows New Briefs

Thumbnail
marijuanamoment.net
28 Upvotes

r/SNDL • • 25d ago

News DEA Opposes Marijuana Rescheduling Opponents' Request For New Testimony And Document Discovery In Ongoing Hearing

Thumbnail
marijuanamoment.net
23 Upvotes

r/SNDL • • 25d ago

Opinion, Not Financial Advice Still here, been awhile! SNDL will be turning new pages!

Post image
29 Upvotes

Been here for a while now(just different accounts), big holding in sndl. Current outlook(positives):

- big foot print in US market: parallel and skymint
- no r/s at recent meeting: investors had spoken
- share buy backs
- positive cash flow(hopefully continuing into future quarters)
- re-evaluate soon $5-$7 possibility

Good luck to all sndl, longhold pays off


r/SNDL • • Oct 15 '26

News SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives

Thumbnail
finance.yahoo.com
40 Upvotes

r/SNDL • • Oct 15 '26

News The resolution for the share consolidation was not approved.

50 Upvotes

The resolution for the share consolidation was not approved at the annual shareholders meeting.


r/SNDL • • Oct 14 '26

News SNDL to Report Third Quarter 2026 Financial Results on October 27, 2026

Thumbnail sndl.com
23 Upvotes

r/SNDL • • Oct 14 '26

Discussion Tomorrow's annual and special meeting ?

14 Upvotes

With tomorrow's annual and special meeting covering the proposed 1-for-2 to 1-for-10 share consolidation, I’m curious to hear everyone's thoughts and/or strategy.
Since it's not about immediate exchange compliance, management has framed it around corporate flexibility, potential institutional appeal, and strategic positioning. While others worry about historical downward pressure or dilution risks.
How are you planning to vote on this?
Do you think there are there any other crucial details from the proxy or financial filings worth keeping in mind before tomorrow?


r/SNDL • • Oct 13 '26

Investments SNDL meldet Rücktritt von Carlo Cannell: Was das für die SNDL-Aktie bedeutet

Thumbnail
ad-hoc-news.de
14 Upvotes

r/SNDL • • Oct 07 '26

News SNDL Announces Resignation of Director

Thumbnail
finance.yahoo.com
37 Upvotes

r/SNDL • • Oct 02 '26

News Annual & Special Meeting Notice: SNDL Inc. --> 10/15/2026 at 10:00 AM, Local

13 Upvotes

Hi,

Just got mail

"SNDL Inc. has announced its Annual & Special Meeting on 10/15/2026 at 10:00 AM, Local Time."

"The following documents have been provided by SNDL Inc..

"

"Company Website: SNDL Inc.
Meeting Date: 10/15/2026
Meeting Location: Live via Webcast: https://meetings.lumiconnect.com/400-607-609-65 password "SNDL2026" (case sensitive)
Record Date: 8/26/2026
CUSIP: 83307B101
ISIN: CA83307B1013
"